Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.68-3.2%$0.83$0.50▼$4.67$37.43M0.7646,704 shs146,070 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics-3.19%-0.27%-19.95%+32.96%-82.32%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.8552 of 5 stars3.42.00.04.21.31.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,323.77% UpsideCurrent Analyst RatingsLatest VMT, CARA, GLOO, XAF, and TNI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M1.79N/AN/A$1.05 per share0.65Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)Latest VMT, CARA, GLOO, XAF, and TNI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.66 million52.36 millionOptionableVMT, CARA, GLOO, XAF, and TNI HeadlinesSourceHeadlineKPRC 2 Athlete of the Week: Cara Pittman, Dawson Softballclick2houston.com - April 20 at 1:55 PMBeing the Marquette women's basketball coach means a lot to Cara Consuegra. She's ready to rebuild.usatoday.com - April 20 at 1:55 PMPort: Who is Cara Mund trying to please?inforum.com - April 20 at 1:55 PMCara Therapeutics Incmoney.usnews.com - April 18 at 7:13 PMCara Therapeutics, Inc. (NASDAQ:CARA) Expected to Earn FY2028 Earnings of ($0.21) Per Shareamericanbankingnews.com - April 15 at 1:52 AMThe Challenge: Zach Nichols reacts to seeing Cara Maria Sorbello back for All Stars 4msn.com - April 14 at 8:54 PMThe Challenge’s Cara Maria Sorbello thought All Stars 4 castmates would reunite due to ‘hatred’ of hermsn.com - April 14 at 8:54 PMNY GOP moves to knock ‘The Biggest Loser’ trainer Cara Castronuova out of Senate primarymsn.com - April 14 at 8:54 PMMarshall Kaufman & Cara Stigger Discusses What Got Them into Lawwhas11.com - April 13 at 7:43 AMBuy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatmentmarkets.businessinsider.com - April 12 at 10:51 PMCara Therapeutics CMO sells shares worth over $2,000investing.com - April 11 at 8:53 PMBuy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market Potentialmarkets.businessinsider.com - April 10 at 5:39 PMNMFTA Bolsters Supply Chain Cybersecurity With Addition of Cara Walls as Cybersecurity Directordcvelocity.com - April 4 at 11:01 PMThe Challenge’s Cara Maria Sorbello reveals one thing she wants to prove on All Stars 4monstersandcritics.com - April 3 at 9:08 PMAshland Police Chief Cara Rossi reinstated today after two months of administrative leavenews.yahoo.com - April 2 at 10:37 AM‘The Biggest Loser’ trainer Cara Castronuova sues NY GOP in bid for Senatemsn.com - April 2 at 10:37 AMCara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conferencemarijuanastocks.com - April 2 at 9:02 AMCara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:00 AMCara Delevingne’s First Song is Really (Really!) Good: Listen Hereyahoo.com - March 30 at 4:51 PMCara Delevingne Wears Trendy Pointy Shoes Out in Londonyahoo.com - March 30 at 8:31 AMAnya Taylor-Joy and Cara Delevingne showcase contrasting styles on glam London night outhellomagazine.com - March 29 at 4:08 PMTracy Beaker fans go wild as Dani Harmer and co-star Cara Readle reunite 19 years after being in Dumping Ground togetherthesun.ie - March 29 at 4:08 PMCara Brindisi Will Make Her Debut Appearance at the Spire Centerbroadwayworld.com - March 29 at 4:08 PMCara Delevingne Gives Sally Bowles a 2024 Upgradevogue.com - March 29 at 4:08 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
